Tags

Type your tag names separated by a space and hit enter

Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Gynecol Endocrinol 2014; 30(6):438-43GE

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine condition that affects fertility through oligo-ovulation, hyperandrogenism and polycystic morphology of the ovaries. Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26). After the treatment, interval several endocrine parameters improved (luteinizing hormone [LH], LH/follicle stimulating hormone [FSH], androstenedione and insulin), insulin response to oral glucose tolerance test reported the significant improvement of insulin sensitivity as well as the gonadotropin-releasing hormone (GnRH)-induced (10 µg, in bolus) LH response. BMI decreased, though no lifestyle modification was requested. When data were analyzed according to the presence or absence of first-grade diabetic relatives, PCOS patients with diabetic relatives showed greater improvement after DCI administration. In conclusion DCI administration is effective in restoring better insulin sensitivity and an improved hormonal pattern in obese hyperinsulinemic PCOS patients, in particular, in hyperinsulinemic PCOS patients who have diabetic relatives.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Gynecological Endocrinology Centre, University of Modena and Reggio Emilia , Modena , Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

24601829

Citation

Genazzani, Alessandro D., et al. "Modulatory Role of D-chiro-inositol (DCI) On LH and Insulin Secretion in Obese PCOS Patients." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 30, no. 6, 2014, pp. 438-43.
Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30(6):438-43.
Genazzani, A. D., Santagni, S., Rattighieri, E., Chierchia, E., Despini, G., Marini, G., ... Simoncini, T. (2014). Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 30(6), pp. 438-43. doi:10.3109/09513590.2014.897321.
Genazzani AD, et al. Modulatory Role of D-chiro-inositol (DCI) On LH and Insulin Secretion in Obese PCOS Patients. Gynecol Endocrinol. 2014;30(6):438-43. PubMed PMID: 24601829.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. AU - Genazzani,Alessandro D, AU - Santagni,Susanna, AU - Rattighieri,Erika, AU - Chierchia,Elisa, AU - Despini,Giulia, AU - Marini,Giulia, AU - Prati,Alessia, AU - Simoncini,Tommaso, Y1 - 2014/03/07/ PY - 2014/3/8/entrez PY - 2014/3/8/pubmed PY - 2015/1/6/medline KW - Body mass index KW - insulin resistance KW - insulin sensitizer KW - polycystic ovary syndrome SP - 438 EP - 43 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 30 IS - 6 N2 - Polycystic ovary syndrome (PCOS) is a common endocrine condition that affects fertility through oligo-ovulation, hyperandrogenism and polycystic morphology of the ovaries. Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26). After the treatment, interval several endocrine parameters improved (luteinizing hormone [LH], LH/follicle stimulating hormone [FSH], androstenedione and insulin), insulin response to oral glucose tolerance test reported the significant improvement of insulin sensitivity as well as the gonadotropin-releasing hormone (GnRH)-induced (10 µg, in bolus) LH response. BMI decreased, though no lifestyle modification was requested. When data were analyzed according to the presence or absence of first-grade diabetic relatives, PCOS patients with diabetic relatives showed greater improvement after DCI administration. In conclusion DCI administration is effective in restoring better insulin sensitivity and an improved hormonal pattern in obese hyperinsulinemic PCOS patients, in particular, in hyperinsulinemic PCOS patients who have diabetic relatives. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/24601829/Modulatory_role_of_D_chiro_inositol__DCI__on_LH_and_insulin_secretion_in_obese_PCOS_patients_ L2 - http://www.tandfonline.com/doi/full/10.3109/09513590.2014.897321 DB - PRIME DP - Unbound Medicine ER -